| Year |
Citation |
Score |
| 2022 |
Trott JF, Aboud OA, McLaughlin B, Anderson KL, Modiano JF, Kim K, Jen KY, Senapedis W, Chang H, Landesman Y, Baloglu E, Pili R, Weiss RH. Anti-Cancer Activity of PAK4/NAMPT Inhibitor and Programmed Cell Death Protein-1 Antibody in Kidney Cancer. Kidney360. 1: 376-388. PMID 35224510 DOI: 10.34067/kid.0000282019 |
0.319 |
|
| 2020 |
Goldsamt A, Damayanti NP, De Nigris F, Pili R. Epigenetic Dysregulation in Advanced Kidney Cancer: Opportunities for Therapeutic Interventions. Cancer Journal (Sudbury, Mass.). 26: 399-406. PMID 32947308 DOI: 10.1097/Ppo.0000000000000479 |
0.405 |
|
| 2020 |
Voss MH, Gordon MS, Mita M, Rini B, Makker V, Macarulla T, Smith DC, Cervantes A, Puzanov I, Pili R, Wang D, Jalal S, Pant S, Patel MR, Neuwirth RL, et al. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. British Journal of Cancer. PMID 32913286 DOI: 10.1038/S41416-020-01041-X |
0.34 |
|
| 2020 |
Kays JK, Koniaris LG, Cooper CA, Pili R, Jiang G, Liu Y, Zimmers TA. The Combination of Low Skeletal Muscle Mass and High Tumor Interleukin-6 Associates with Decreased Survival in Clear Cell Renal Cell Carcinoma. Cancers. 12. PMID 32560494 DOI: 10.3390/Cancers12061605 |
0.354 |
|
| 2020 |
Affronti HC, Rowsam AM, Pellerite AJ, Rosario SR, Long MD, Jacobi JJ, Bianchi-Smiraglia A, Boerlin CS, Gillard BM, Karasik E, Foster BA, Moser M, Wilton JH, Attwood K, Nikiforov MA, ... ... Pili R, et al. Pharmacological polyamine catabolism upregulation with methionine salvage pathway inhibition as an effective prostate cancer therapy. Nature Communications. 11: 52. PMID 31911608 DOI: 10.1038/S41467-019-13950-4 |
0.367 |
|
| 2020 |
Trott JF, Abu Aboud O, McLaughlin B, Anderson KL, Modiano JF, Kim K, Jen K, Senapedis W, Chang H, Landesman Y, Baloglu E, Pili R, Weiss RH. Anti-Cancer Activity of PAK4/NAMPT Inhibitor and Programmed Cell Death Protein-1 Antibody in Kidney Cancer Kidney360. 1: 376-388. DOI: 10.34067/Kid.0000282019 |
0.453 |
|
| 2020 |
Adra N, Hauke RJ, Kaimakliotis HZ, Gulati S, Hashemi N, Pili R. Phase II trial of atezolizumab plus chemotherapy after progression on single-agent PD-1 or PD-L1 inhibitor in cisplatin ineligible patients with advanced urothelial carcinoma HCRN GU17-295. Journal of Clinical Oncology. 38: TPS587-TPS587. DOI: 10.1200/Jco.2020.38.6_Suppl.Tps587 |
0.335 |
|
| 2020 |
Pili R, Adra N, Damayanti N, Logan TF, Narayan V, Monk P, Dropcho S, Sego LM, Liu H, Althouse SK, Haas NB. Immunomodulation by HDAC inhibition: Results from a phase I study with entinostat in combination with atezolizumab and bevacizumab in metastatic renal cell carcinoma patients. Journal of Clinical Oncology. 38: 5064-5064. DOI: 10.1200/Jco.2020.38.15_Suppl.5064 |
0.376 |
|
| 2019 |
Wood A, George S, Adra N, Chintala S, Damayanti N, Pili R. Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma. Investigational New Drugs. PMID 31654285 DOI: 10.1007/S10637-019-00864-7 |
0.361 |
|
| 2019 |
Shen L, Pili R. Tasquinimod targets suppressive myeloid cells in the tumor microenvironment. Oncoimmunology. 8: e1072672. PMID 31646064 DOI: 10.1080/2162402X.2015.1072672 |
0.366 |
|
| 2019 |
Elbanna M, Orillion AR, Damayanti NP, Adelaiye-Ogala R, Shen L, Miles KM, Chintala S, Ciamporcero E, Ramakrishnan S, Ku SY, Rex K, Caenepeel S, Coxon A, Pili R. Dual inhibition of angiopoietin-TIE2 and MET alters the tumor microenvironment and prolongs survival in a metastatic model of renal cell carcinoma. Molecular Cancer Therapeutics. PMID 31582532 DOI: 10.1158/1535-7163.Mct-18-1202 |
0.6 |
|
| 2019 |
Fishel ML, Xia H, McGeown J, McIlwain DW, Elbanna M, Craft AA, Kaimakliotis HZ, Sandusky GE, Zhang C, Pili R, Kelley MR, Jerde TJ. Anti-tumor activity and mechanistic characterization of APE1/Ref-1 inhibitors in bladder cancer. Molecular Cancer Therapeutics. PMID 31413178 DOI: 10.1158/1535-7163.Mct-18-1166 |
0.438 |
|
| 2019 |
Bunch B, Krishnan N, Greenspan RD, Ramakrishnan S, Attwood K, Yan L, Qi Q, Wang D, Morrison C, Omilian A, Bshara W, Pili R, Trump DL, Johnson C, Woloszynska A. TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC). Cell Cycle (Georgetown, Tex.). 1-12. PMID 31318640 DOI: 10.1080/15384101.2019.1638693 |
0.573 |
|
| 2019 |
Michaelson MD, Gupta S, Agarwal N, Szmulewitz R, Powles T, Pili R, Bruce JY, Vaishampayan U, Larkin J, Rosbrook B, Wang E, Murphy D, Wang P, Lechuga MJ, Valota O, et al. A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors. The Oncologist. PMID 31171735 DOI: 10.1634/Theoncologist.2018-0749 |
0.447 |
|
| 2019 |
Gawronski AR, Lin YY, McConeghy B, LeBihan S, Asghari H, Koçkan C, Orabi B, Adra N, Pili R, Collins CC, Sahinalp SC, Hach F. Structural variation and fusion detection using targeted sequencing data from circulating cell free DNA. Nucleic Acids Research. PMID 30759232 DOI: 10.1093/Nar/Gkz067 |
0.347 |
|
| 2019 |
George S, Herbst L, Sikorski M, Diraddo AM, Azabdaftari G, Roche C, Kauffman E, Li Q, Schwaab T, Levine EG, Pili R, Chatta GS, Appleman LJ, Groman A, Parikh RA, et al. A phase I/II trial of pazopanib alternating with bevacizumab in treatment-naïve metastatic clear cell renal cell carcinoma (CCRCC) patients: Phase I results. Journal of Clinical Oncology. 37: 561-561. DOI: 10.1200/Jco.2019.37.7_Suppl.561 |
0.359 |
|
| 2019 |
Pili R, Quinn DI, Albany C, Adra N, Logan TF, Greenspan A, Budka J, Damayanti N, Green MA, Fletcher JW, Tann M, Edwards SI, Burney H, Liu H, Hahn NM. Immunomodulation by HDAC inhibition: Results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, renal, and prostate carcinoma patients. Journal of Clinical Oncology. 37: 2572-2572. DOI: 10.1200/Jco.2019.37.15_Suppl.2572 |
0.418 |
|
| 2019 |
Damayanti NP, Budka JA, Ordaz JD, Orillion A, Ahmed K, Chu X, Wang Y, Liu Y, Pili R. Abstract A184: T-cell rejuvenation is associated with vorinostat-induced immune response in combination with immune checkpoint blockade Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A184 |
0.417 |
|
| 2019 |
Elbanna M, Budka J, Dausinas P, Adelaiye-Ogala R, Damayanti N, Orillion A, Banno E, Fontana L, Pili R. Abstract 1611: Caloric restriction potentiates the therapeutic benefit of androgen deprivation therapy and alters macrophage polarization when combined with PD1 inhibition in murine models of prostate cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-1611 |
0.352 |
|
| 2019 |
Budka J, Damayanti N, Pili R. Abstract 2366: HDAC inhibition improves immune checkpoint inhibitor efficacy in renal cell carcinoma Cancer Research. 79: 2366-2366. DOI: 10.1158/1538-7445.Am2019-2366 |
0.437 |
|
| 2018 |
Orillion AR, Damayanti NP, Shen L, Adelaiye-Ogala R, Affronti HC, Elbanna M, Chintala S, Ciesielski MJ, Fontana L, Kao C, Elzey BD, Ratliff TL, Nelson DE, Smiraglia DJ, Abrams SI, ... Pili R, et al. Dietary protein restriction reprograms tumor associated macrophages and enhances immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30190370 DOI: 10.1158/1078-0432.Ccr-18-0980 |
0.324 |
|
| 2018 |
Monk P, Liu G, Stadler WM, Geyer S, Huang Y, Wright J, Villalona-Calero M, Wade J, Szmulewitz R, Gupta S, Mortazavi A, Dreicer R, Pili R, Dawson N, George S, et al. Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Investigational New Drugs. PMID 30083962 DOI: 10.1007/S10637-018-0630-9 |
0.403 |
|
| 2018 |
Damayanti NP, Budka JA, Khella HWZ, Ferris MW, Ku SY, Kauffman EC, Wood AC, Ahmed K, Chintala VN, Adelaiye-Ogala R, Elbanna M, Orillion AR, Chintala S, Kao C, Linehan WM, ... ... Pili R, et al. Therapeutic targeting of TFE3/IRS-1/PI3K/mTOR axis in translocation renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30061365 DOI: 10.1158/1078-0432.Ccr-18-0269 |
0.389 |
|
| 2018 |
Thompson JA, Motzer RJ, Molina AM, Choueiri TK, Heath EI, Redman BG, Sangha RS, Ernst DS, Pili R, Kim SK, Reyno L, Wiseman A, Trave F, Anand B, Morrison K, et al. Phase 1 Trials of anti-ENPP3 antibody drug conjugates in advanced refractory renal cell carcinomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29848572 DOI: 10.1158/1078-0432.Ccr-18-0481 |
0.344 |
|
| 2018 |
Adelaiye-Ogala R, Damayanti NP, Orillion AR, Arisa S, Chintala S, Titus MA, Kao C, Pili R. Therapeutic targeting of sunitinib-induced AR phosphorylation in renal cell carcinoma. Cancer Research. PMID 29572225 DOI: 10.1158/0008-5472.Can-17-3386 |
0.426 |
|
| 2018 |
Ciamporcero E, Daga M, Pizzimenti S, Roetto A, Dianzani C, Compagnone A, Palmieri A, Ullio C, Cangemi L, Pili R, Barrera G. Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancer. Free Radical Biology & Medicine. 115: 447-457. PMID 29248722 DOI: 10.1016/J.Freeradbiomed.2017.12.005 |
0.388 |
|
| 2018 |
Hashemi-Sadraei N, Perrino CM, Monn MF, Bandali E, Cheng L, Idrees M, Bihrle R, Koch MO, Eble J, Kao C, Albany C, Pili R, Grignon DA, Kaimakliotis HZ. Plasmacytoid urothelial carcinoma: A clinicopathological study. Journal of Clinical Oncology. 36: 482-482. DOI: 10.1200/Jco.2018.36.6_Suppl.482 |
0.313 |
|
| 2018 |
Gbolahan OB, Hashemi-Sadraei N, Conteh A, Kaimakliotis HZ, Storkus W, Pili R, Logan TF. Clinical features and survival outcomes in a prospective spontaneous regression (SR) protocol of renal cell carcinoma (RCC) and melanoma (M) patients. Journal of Clinical Oncology. 36: e16585-e16585. DOI: 10.1200/Jco.2018.36.15_Suppl.E16585 |
0.333 |
|
| 2018 |
Hashemi-Sadraei N, Perrino CM, Monn MF, Bandali E, Cheng L, Idrees M, Bihrle R, Koch MO, Eble J, Kao C, Adra N, Pili R, Grignon DA, Kaimakliotis HZ, Albany C. Survival outcomes in plasmacytoid urothelial carcinoma: Results with contemporary systemic therapy. Journal of Clinical Oncology. 36: e16525-e16525. DOI: 10.1200/Jco.2018.36.15_Suppl.E16525 |
0.323 |
|
| 2018 |
Damayanti NP, Ahmed K, Elbanna M, Kao C, Pili R. Abstract 3109: Investigating the role of wild-type TFE3 in renal cell carcinoma cells harboring TFE3 fusions with spliceosome machinery associated genes Cancer Research. 78: 3109-3109. DOI: 10.1158/1538-7445.Am2018-3109 |
0.398 |
|
| 2018 |
Elbanna MF, Damayanti N, Chintala S, Pili R. Abstract 1825: PIK3CA E542K mutation in bladder cancer confers resistance to PI3K targeted therapy but synergy with BET inhibition Cancer Research. 78: 1825-1825. DOI: 10.1158/1538-7445.Am2018-1825 |
0.349 |
|
| 2017 |
Affronti HC, Long MD, Rosario SR, Gillard BM, Karasik E, Boerlin CS, Pellerite AJ, Foster BA, Attwood K, Pili R, Wilton JH, Campbell MJ, Smiraglia DJ. Dietary folate levels alter the kinetics and molecular mechanism of prostate cancer recurrence in the CWR22 model. Oncotarget. 8: 103758-103774. PMID 29262598 DOI: 10.18632/Oncotarget.21911 |
0.358 |
|
| 2017 |
Ramakrishnan S, Hu Q, Krishnan N, Wang D, Smit E, Granger V, Rak M, Attwood K, Johnson C, Morrison C, Pili R, Chatta G, Guru K, Gueron G, McNally L, et al. Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer. Cell Death & Disease. 8: 3217. PMID 29242529 DOI: 10.1038/S41419-017-0024-5 |
0.572 |
|
| 2017 |
Paller CJ, Zhou XC, Heath EI, Taplin ME, Mayer T, Stein MN, Bubley GJ, Pili R, Hudson T, Kakarla R, Abbas MM, Anders NM, Dowling D, King S, Bruns AB, et al. Muscadine Grape Skin Extract in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29113986 DOI: 10.1158/1078-0432.Ccr-17-1100 |
0.351 |
|
| 2017 |
Adelaiye-Ogala R, Budka J, Damayanti NP, Arrington J, Ferris MW, Hsu CC, Chintala S, Orillion AR, Miles KM, Shen L, Elbanna M, Ciamporcero E, Arisa S, Pettazzoni P, Draetta GF, ... ... Pili R, et al. EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming. Cancer Research. PMID 28978636 DOI: 10.1158/0008-5472.Can-17-0899 |
0.445 |
|
| 2017 |
Pili R, Quinn DI, Hammers H, Monk JP, George S, Dorff T, Olencki T, Shen L, Orillion AR, Lamonica D, Fragomeni RAS, Szabo Z, Hutson AD, Groman A, Perkins SM, et al. Immunomodulation by entinostat in renal cell carcinoma patients receiving high dose interleukin 2: a multicenter, single-arm, phase 1/2 trial (NCI-CTEP#7870). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28939740 DOI: 10.1158/1078-0432.Ccr-17-1178 |
0.39 |
|
| 2017 |
Wentink MQ, Verheul HMW, Pal SK, George S, Voortman J, Danchaivijitr P, Adelaiye R, Poslinski D, Groman A, Hutson A, Pili R. Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma. Clinical Genitourinary Cancer. PMID 28781191 DOI: 10.1016/J.Clgc.2017.07.004 |
0.409 |
|
| 2017 |
Orillion A, Hashimoto A, Damayanti NP, Shen L, Adelaiye-Ogala R, Arisa S, Chintala S, Ordentlich P, Kao C, Elzey B, Gabrilovich D, Pili R. Entinostat neutralizes myeloid derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28698201 DOI: 10.1158/1078-0432.Ccr-17-0741 |
0.416 |
|
| 2017 |
Sanfrancesco JM, Eble JN, Grignon DJ, Wang M, Zhang S, Sundaram CP, Idrees MT, Pili R, Kouba E, Cheng L. Preservation of Truncal Genomic Alterations in Clear Cell and Papillary Renal Cell Carcinomas with Sarcomatoid Features: An Intra- and Intertumoral, Multifocal Fluorescence in Situ Hybridization Analysis Reveals Limited Genetic Heterogeneity. Molecular Carcinogenesis. PMID 28667776 DOI: 10.1002/Mc.22699 |
0.375 |
|
| 2017 |
Pili R, Jegede O, Carducci MA, Manola J, Groteluschen DL, Appleman LL, Liu G, Shanks JC, Dakhil SR, Dutcher J, DiPaola RS. A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805]). Clinical Genitourinary Cancer. PMID 28545998 DOI: 10.1016/J.Clgc.2017.04.023 |
0.392 |
|
| 2017 |
Marshall JR, Burk RF, Ondracek RP, Hill KE, Perloff M, Davis W, Pili R, George S, Bergan R. Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men. Oncotarget. PMID 28412747 DOI: 10.18632/Oncotarget.15460 |
0.382 |
|
| 2017 |
Pili R, Liu G, Chintala S, Verheul H, Rehman S, Attwood K, Lodge MA, Wahl R, Martin JI, Miles KM, Paesante S, Adelaiye R, Godoy A, King S, Zwiebel J, et al. Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial. British Journal of Cancer. PMID 28222071 DOI: 10.1038/Bjc.2017.33 |
0.415 |
|
| 2017 |
Huang W, Chang CL, Brault ND, Gur O, Wang Z, Jalal SI, Low PS, Ratliff TL, Pili R, Savran CA. Separation and dual detection of prostate cancer cells and protein biomarkers using a microchip device. Lab On a Chip. PMID 28054089 DOI: 10.1039/C6Lc01279E |
0.363 |
|
| 2017 |
Paller CJ, Heath EI, Taplin M, Stein MN, Bubley GJ, Pili R, Mayer TM, Zhou XC, Hudson T, Abbas M, Anders N, Dowling D, KIng S, Drake CG, Antonarakis ES, et al. A phase II study of muscadine grape skin extract in men with biochemically recurrent prostate cancer. Journal of Clinical Oncology. 35: 248-248. DOI: 10.1200/Jco.2017.35.6_Suppl.248 |
0.36 |
|
| 2017 |
Michaelson MD, Gupta S, Agarwal N, Szmulewitz RZ, Powles T, Pili R, Bruce JY, Vaishampayan UN, Larkin JMG, Rosbrook B, Lechuga M, Valota O, Tarazi JC, Shepard DR. Axitinib plus crizotinib in patients with advanced solid tumors and metastatic renal cell carcinoma (mRCC): Preliminary phase 1b results. Journal of Clinical Oncology. 35: 2551-2551. DOI: 10.1200/Jco.2017.35.15_Suppl.2551 |
0.342 |
|
| 2017 |
Chintala S, Adelaiye-Ogala R, Orillion A, Arisa S, Elbanna M, Damayanti NP, Pili R. Abstract 94: Association of xCT overexpression with RTKI resistance and metastases in clear cell renal cell carcinoma Cancer Research. 77: 94-94. DOI: 10.1158/1538-7445.Am2017-94 |
0.369 |
|
| 2017 |
Elbanna M, Chintala S, Ciamporcero E, Adelayie R, Orillion A, Arisa S, Damayanti N, Grimard M, Puls T, Harbin S, Fishel M, Pili R. Abstract 5783:In vitromodeling of patient derived bladder cancer cell lines in 3D culture systems Cancer Research. 77: 5783-5783. DOI: 10.1158/1538-7445.Am2017-5783 |
0.313 |
|
| 2017 |
Damayanti NP, Chintala S, Orillion A, Adelaiye-Ogala R, Elbanna MF, Hollenhorst P, Pili R. Abstract 4475: Delineating translocation renal cell carcinoma oncogenesis in cells harboring TFE3 fusion with spliceosome machinery associated genes Cancer Research. 77: 4475-4475. DOI: 10.1158/1538-7445.Am2017-4475 |
0.346 |
|
| 2017 |
Adelaiye-Ogala RM, Chintala S, Orillion A, Elbanna M, Elzey B, Damayanti N, Miles KM, Kao C, Pettazzoni P, Draetta GF, Pili R. Abstract 4170: Targeting androgen receptor overcomes resistance to tyrosine kinase inhibitors in advanced clear cell renal cell carcinoma Cancer Research. 77: 4170-4170. DOI: 10.1158/1538-7445.Am2017-4170 |
0.376 |
|
| 2017 |
Orillion AR, Chintala S, Adelaiye-Ogala R, Shen L, Damayanti N, Elbanna M, Arisa S, Elzey B, Kao C, Fontana L, Pili R. Abstract 250: Methionine restriction increases macrophage tumoricidal activity and significantly inhibits prostate cancer growth Cancer Research. 77: 250-250. DOI: 10.1158/1538-7445.Am2017-250 |
0.424 |
|
| 2016 |
Adra N, Cheng L, Pili R. Unclassified Renal Cell Carcinoma With Significant Response to Nivolumab. Clinical Genitourinary Cancer. PMID 28110836 DOI: 10.1016/J.Clgc.2016.12.019 |
0.336 |
|
| 2016 |
Wei L, Chintala S, Ciamporcero E, Ramakrishnan S, Elbanna M, Wang J, Hu Q, Glenn ST, Murakami M, Liu L, Cortes Gomez E, Sun Y, Conroy J, Miles KM, Malathi K, ... ... Pili R, et al. Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts. Oncotarget. PMID 27823983 DOI: 10.18632/Oncotarget.13062 |
0.56 |
|
| 2016 |
Wentink MQ, Broxterman HJ, Lam SW, Boven E, Walraven M, Griffioen AW, Pili R, van der Vliet HJ, de Gruijl TD, Verheul HM. A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer. British Journal of Cancer. PMID 27575850 DOI: 10.1038/Bjc.2016.275 |
0.316 |
|
| 2016 |
Deng X, Shao G, Zhang HT, Li C, Zhang D, Cheng L, Elzey BD, Pili R, Ratliff TL, Huang J, Hu CD. Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth. Oncogene. PMID 27546619 DOI: 10.1038/Onc.2016.287 |
0.415 |
|
| 2016 |
Ramakrishnan S, Ku S, Ciamporcero E, Miles KM, Attwood K, Chintala S, Shen L, Ellis L, Sotomayor P, Swetzig W, Huang R, Conroy D, Orillion A, Das G, Pili R. HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma. Bmc Cancer. 16: 617. PMID 27506904 DOI: 10.1186/S12885-016-2604-7 |
0.571 |
|
| 2016 |
Radovich M, Kiel PJ, Nance SM, Niland EE, Parsley ME, Ferguson ME, Jiang G, Ammakkanavar NR, Einhorn LH, Cheng L, Nassiri M, Davidson DD, Rushing DA, Loehrer PJ, Pili R, et al. Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers. Oncotarget. PMID 27447854 DOI: 10.18632/Oncotarget.10606 |
0.367 |
|
| 2016 |
Sternberg C, Armstrong A, Pili R, Ng S, Huddart R, Agarwal N, Khvorostenko D, Lyulko O, Brize A, Vogelzang N, Delva R, Harza M, Thanos A, James N, Werbrouck P, et al. Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27298414 DOI: 10.1200/Jco.2016.66.9697 |
0.392 |
|
| 2016 |
Ellis L, Ku S, Li Q, Azabdaftari G, Seliski J, Olson B, Netherby CS, Tang DG, Abrams SI, Goodrich DW, Pili R. Generation of a C57BL/6 MYC-driven mouse model and cell line of prostate cancer. The Prostate. PMID 27225803 DOI: 10.1002/Pros.23206 |
0.397 |
|
| 2016 |
Wang J, Papanicolau-Sengos A, Chintala S, Wei L, Liu B, Hu Q, Miles KM, Conroy JM, Glenn ST, Costantini M, Magi-Galluzzi C, Signoretti S, Choueiri T, Gallucci M, Sentinelli S, ... ... Pili R, et al. Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation. Oncotarget. PMID 27144525 DOI: 10.18632/Oncotarget.9093 |
0.334 |
|
| 2016 |
Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, ... ... Pili R, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet (London, England). PMID 26969090 DOI: 10.1016/S0140-6736(16)00559-6 |
0.403 |
|
| 2016 |
Shen L, Orillion A, Pili R. Histone deacetylase inhibitors as immunomodulators in cancer therapeutics. Epigenomics. PMID 26950532 DOI: 10.2217/Epi.15.118 |
0.443 |
|
| 2016 |
Pili R, Quinn DI, Hammers HJ, Monk P, George S, Dorff TB, Olencki T, Shen L, Hutson A, Piekarz R, Carducci MA. Immunomodulation by HDAC inhibition: Results from a phase II study with entinostat and high-dose Interleukin 2 in renal cell carcinoma patients (CTEP#7870). Journal of Clinical Oncology. 34: 500-500. DOI: 10.1200/Jco.2016.34.2_Suppl.500 |
0.369 |
|
| 2016 |
Sternberg CN, Armstrong AJ, Pili R, Nederman T, Carducci MA. A Phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castration-resistant prostate cancer (mCRPC), secondary endpoints. Journal of Clinical Oncology. 34: 239-239. DOI: 10.1200/Jco.2016.34.2_Suppl.239 |
0.356 |
|
| 2016 |
Pili R, Quinn D, Hahn NM, Albany C, Logan TF, Drake CG. A phase I/Ib, open-label, dose-finding study to evaluate safety, pharmacodynamics, and efficacy of pembrolizumab (MK-3475) in combination with vorinostat in patients with advanced renal or urothelial cell carcinoma. Journal of Clinical Oncology. 34: TPS4581-TPS4581. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps4581 |
0.377 |
|
| 2016 |
Trump DL, Brady WE, Aragon-Ching JB, Pili R, Levine EG, George S, Johnson CS. A phase I/II trial of ketoconazole + calcitriol [1,25(OH)2D3] in castration-resistant prostate cancer. Journal of Clinical Oncology. 34: 5065-5065. DOI: 10.1200/Jco.2016.34.15_Suppl.5065 |
0.371 |
|
| 2016 |
Pili R, Quinn DI, Hammers HJ, Monk JP, George S, Dorff TB, Olencki T, Shen L, Lamonica D, Hutson A, Groman A, Perkins SM, Piekarz R, Carducci M. Abstract CT015: Results from a phase I/II study with the HDAC inhibitor entinostat in combination with high-dose interleukin-2 in renal cell carcinoma patients (CTEP#7870) Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Ct015 |
0.408 |
|
| 2016 |
Chintala S, Adelaiye-Ogala R, Orillion A, Arisa S, Elbanna M, Pili R. Abstract 955: Inhibition of SEC24D decreases exosome release of the tumor suppressor miR-605 in renal cell carcinoma Cancer Research. 76: 955-955. DOI: 10.1158/1538-7445.Am2016-955 |
0.345 |
|
| 2016 |
Orillion A, Adelaiye-Ogala R, Shen L, Ciamporcero E, Elbanna M, Chintala S, Arisa S, Elzey B, Kao C, Fontana L, Pili R. Abstract 897: Methionine restriction alters functional polarization of macrophages in a murine model of prostate cancer Cancer Research. 76: 897-897. DOI: 10.1158/1538-7445.Am2016-897 |
0.369 |
|
| 2016 |
Orillion AR, Shen L, Adelaiye-Ogala R, Elbanna M, Chintala S, Arisa S, Pili R. Abstract 4906: The selective class I HDAC inhibitor entinostat enhances the antitumor effect of PD-1 inhibition in a syngeneic orthotopic murine model of renal cell carcinoma Cancer Research. 76: 4906-4906. DOI: 10.1158/1538-7445.Am2016-4906 |
0.429 |
|
| 2016 |
Elbanna MF, Ciamporcero E, Adelaiye R, Orillion A, Chintala S, Pili R. Abstract 384: Differential response to a dual PI3K/mTOR inhibitor in PIK3CA mutant urothelial cancer patient derived xenografts Cancer Research. 76: 384-384. DOI: 10.1158/1538-7445.Am2016-384 |
0.355 |
|
| 2016 |
Adelaiye-Ogala RM, Chintala S, Orillion A, Pettazzoni P, Elbanna M, Elzey B, Miles KM, Kao C, Draetta GF, Pili R. Abstract 2126: Androgen receptor expression is associated with sunitinib resistance in renal cell carcinoma models Cancer Research. 76: 2126-2126. DOI: 10.1158/1538-7445.Am2016-2126 |
0.429 |
|
| 2016 |
Kaimakliotis H, Koch M, Kao L, Cho J, Bihrle R, Pili R, Cary C, Masterson T, Albany C, Foster R, Reid J, Timms K, Cheng L, Stone S. MP49-02 A STUDY TO EVALUATE THE PROGNOSTIC AND PREDICTIVE UTILITY OF CCP AND HRD ASSAYS AND GENETIC SEQUENCING IN PATIENTS UNDERGOING NEOADJUVANT CHEMOTHERAPY IN BLADDER CANCER Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.415 |
0.309 |
|
| 2015 |
Montgomery B, Eisenberger MA, Rettig MB, Chu FM, Pili R, Stephenson J, Vogelzang NJ, Koletsky AJ, Nordquist LT, Edenfield WJ, Mamlouk K, Ferrante KJ, Taplin ME. Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26527750 DOI: 10.1158/1078-0432.Ccr-15-1432 |
0.393 |
|
| 2015 |
Pokuri VK, Syed JR, Yang Z, Field EP, Cyriac S, Pili R, Levine EG, Azabdaftari G, Trump DL, Guru K, George S. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. Clinical Genitourinary Cancer. PMID 26508364 DOI: 10.1016/J.Clgc.2015.09.013 |
0.322 |
|
| 2015 |
Lamming DW, Cummings NE, Rastelli AL, Gao F, Cava E, Bertozzi B, Spelta F, Pili R, Fontana L. Restriction of dietary protein decreases mTORC1 in tumors and somatic tissues of a tumor-bearing mouse xenograft model. Oncotarget. PMID 26378060 DOI: 10.18632/Oncotarget.5180 |
0.388 |
|
| 2015 |
Kalmuk J, Folaron M, Buchinger J, Pili R, Seshadri M. Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer. Oncotarget. 6: 24376-92. PMID 26203773 DOI: 10.18632/Oncotarget.4463 |
0.432 |
|
| 2015 |
Ciamporcero E, Shen H, Ramakrishnan S, Yu Ku S, Chintala S, Shen L, Adelaiye R, Miles KM, Ullio C, Pizzimenti S, Daga M, Azabdaftari G, Attwood K, Johnson C, Zhang J, ... ... Pili R, et al. YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene. PMID 26119935 DOI: 10.1038/Onc.2015.219 |
0.616 |
|
| 2015 |
Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, ... ... Pili R, et al. Testicular Cancer, Version 2.2015. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 772-99. PMID 26085393 DOI: 10.6004/Jnccn.2015.0092 |
0.387 |
|
| 2015 |
Weiss A, Ding X, van Beijnum JR, Wong I, Wong TJ, Berndsen RH, Dormond O, Dallinga M, Shen L, Schlingemann RO, Pili R, Ho CM, Dyson PJ, van den Bergh H, Griffioen AW, et al. Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer. Angiogenesis. 18: 233-44. PMID 25824484 DOI: 10.1007/S10456-015-9462-9 |
0.327 |
|
| 2015 |
Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, ... ... Pili R, et al. Kidney cancer, version 3.2015. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 151-9. PMID 25691606 DOI: 10.6004/Jnccn.2015.0022 |
0.405 |
|
| 2015 |
Kirk JS, Schaarschuch K, Dalimov Z, Lasorsa E, Ku S, Ramakrishnan S, Hu Q, Azabdaftari G, Wang J, Pili R, Ellis L. Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer. Oncotarget. 6: 3136-46. PMID 25605014 DOI: 10.18632/Oncotarget.3077 |
0.643 |
|
| 2015 |
Adelaiye R, Ciamporcero E, Miles KM, Sotomayor P, Bard J, Tsompana M, Conroy D, Shen L, Ramakrishnan S, Ku SY, Orillion A, Prey J, Fetterly G, Buck M, Chintala S, ... ... Pili R, et al. Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications. Molecular Cancer Therapeutics. 14: 513-22. PMID 25519701 DOI: 10.1158/1535-7163.Mct-14-0208 |
0.6 |
|
| 2015 |
Ciamporcero E, Miles KM, Adelaiye R, Ramakrishnan S, Shen L, Ku S, Pizzimenti S, Sennino B, Barrera G, Pili R. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Molecular Cancer Therapeutics. 14: 101-10. PMID 25381264 DOI: 10.1158/1535-7163.Mct-14-0094 |
0.611 |
|
| 2015 |
Shen L, Sundstedt A, Ciesielski M, Miles KM, Celander M, Adelaiye R, Orillion A, Ciamporcero E, Ramakrishnan S, Ellis L, Fenstermaker R, Abrams SI, Eriksson H, Leanderson T, Olsson A, ... Pili R, et al. Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer Immunology Research. 3: 136-48. PMID 25370534 DOI: 10.1158/2326-6066.Cir-14-0036 |
0.639 |
|
| 2015 |
Pili R, Manola J, Carducci MA, Dutcher JP, Appleman LJ, Groteluschen DL, DiPaola RS. Randomized phase II study of two different doses of AVE0005 (VEGF Trap, aflibercept) in patients (pts) with metastatic renal cell carcinoma (RCC): An ECOG-ACRIN study [E4805]. Journal of Clinical Oncology. 33: 4549-4549. DOI: 10.1200/Jco.2015.33.15_Suppl.4549 |
0.372 |
|
| 2015 |
Haas NB, Manola J, Flaherty K, Uzzo RG, Atkins MB, Dutcher JP, Wood CG, Kane CJ, Jewett MAS, Coomes B, Matin SF, Kuzel T, Sexton WJ, Wong Y, Choueiri TK, ... Pili R, et al. Dose analysis of ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase 3 trial. Journal of Clinical Oncology. 33: 4508-4508. DOI: 10.1200/Jco.2015.33.15_Suppl.4508 |
0.333 |
|
| 2015 |
Thompson JA, Motzer R, Molina AM, Choueiri TK, Heath EI, Kollmannsberger CK, Redman BG, Sangha RS, Ernst DS, Pili R, Butturini A, Wiseman A, Trave F, Anand B, Huang Y, et al. Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RRCC). Journal of Clinical Oncology. 33: 2503-2503. DOI: 10.1200/Jco.2015.33.15_Suppl.2503 |
0.355 |
|
| 2015 |
Pokuri VK, Syed JR, Yang Z, Field EP, Cyriac S, Azabdaftari G, Pili R, Levine EG, Trump DL, Hutson A, Guru K, George S. Predictors of complete pathological response (pT0) to neoadjuvant chemotherapy (NAC) in muscle-invasive bladder carcinoma (MIBC). Journal of Clinical Oncology. 33: e15534-e15534. DOI: 10.1200/Jco.2014.32.15_Suppl.E15501 |
0.308 |
|
| 2015 |
Adelaiye-Ogala RM, Shen L, Chintala S, Ciamporcero E, Orillion A, Elbanna M, Ku S, Miles KM, Gillard B, Buck M, Pili R. Abstract 4132: Anti-tumor and anti-metastatic effect of sunitinib in a patient derived metastatic clear cell renal cell carcinoma xenograft model Cancer Research. 75: 4132-4132. DOI: 10.1158/1538-7445.Am2015-4132 |
0.422 |
|
| 2015 |
Shen L, Pierron V, Bauchet A, Nakhle J, Orillion A, Adelaiye R, Ciamporcero E, Meyer-Losic F, Eriksson H, Lassau N, Leguerney I, Schmidlin F, Olsson A, Pili R. Abstract 4120: Tasquinimod inhibits local invasion and metastases in two preclinical models of renal cell carcinoma Cancer Research. 75: 4120-4120. DOI: 10.1158/1538-7445.Am2015-4120 |
0.352 |
|
| 2015 |
Orillion A, Adelaiye-Ogala R, Shen L, Ciamporcero E, Ku SY, Ramakrishnan S, Elbanna M, Chintala S, Pili R. Abstract 4110: Inhibition of angiopoietin 1/2 and c-MET impairs metastatic potential in a patient derived xenograft of renal carcinoma Cancer Research. 75: 4110-4110. DOI: 10.1158/1538-7445.Am2015-4110 |
0.597 |
|
| 2015 |
Adelaiye-Ogala RM, Chintala S, Shen L, Orillion A, Ciamporcero E, Elbanna M, Miles KM, Gillard B, Buck M, Pili R. Abstract 3508: Inhibition of EZH2 overcomes resistance to sunitinib in clear cell renal cell carcinoma models Cancer Research. 75: 3508-3508. DOI: 10.1158/1538-7445.Am2015-3508 |
0.466 |
|
| 2015 |
Ku S, Ramakrishnan S, Ciamporcero E, Xu B, Azabdaftari G, Cheney R, Pili R. Abstract 2546: HDAC and Hsp90 inhibition as therapeutic strategy for translocation renal cell carcinoma Cancer Research. 75: 2546-2546. DOI: 10.1158/1538-7445.Am2015-2546 |
0.651 |
|
| 2015 |
Shen L, Orillion A, Adelaiye R, Ciamporcero E, Ramakrishnan S, Pili R. Abstract 2514: Activity of a novel Foxp3-tumor cell vaccine in a murine model of renal cell carcinoma Cancer Research. 75: 2514-2514. DOI: 10.1158/1538-7445.Am2015-2514 |
0.585 |
|
| 2015 |
Elbanna MF, Ciamporcero E, Ramakrishnan S, Adelaiye R, Shen L, Orillion A, Ku S, Chintala S, Pili R. Abstract 1462: Characterization of patient-derived bladder cancer xenografts: role of xCT in response to cisplatin Cancer Research. 75: 1462-1462. DOI: 10.1158/1538-7445.Am2015-1462 |
0.591 |
|
| 2015 |
Voss M, Gordon M, Mita M, Rini B, Makker V, Macarulla T, Smith D, Kwak E, Cervantes A, Puzanov I, Pili R, Wang D, Jalal S, Pant S, Patel M, et al. 354 Phase I study of investigational oral mTORC1/2 inhibitor MLN0128: Expansion phase in patients with renal, endometrial, or bladder cancer European Journal of Cancer. 51: S72. DOI: 10.1016/S0959-8049(16)30217-9 |
0.353 |
|
| 2014 |
Taplin M, Chi KN, Chu F, Cochran J, Edenfield WJ, Eisenberger M, Emmenegger U, Heath EI, Hussain A, Koletsky A, Lipsitz D, Nordquist L, Pili R, Rettig M, Sartor O, et al. 757OGALETERONE IN 4 PATIENT POPULATIONS OF MEN WITH CRPC: RESULTS FROM ARMOR2. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv257. PMID 28174829 DOI: 10.1093/Annonc/Mdu336.5 |
0.307 |
|
| 2014 |
Miles KM, Seshadri M, Ciamporcero E, Adelaiye R, Gillard B, Sotomayor P, Attwood K, Shen L, Conroy D, Kuhnert F, Lalani AS, Thurston G, Pili R. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts. Plos One. 9: e112371. PMID 25393540 DOI: 10.1371/Journal.Pone.0112371 |
0.434 |
|
| 2014 |
Armstrong AJ, Kaboteh R, Carducci MA, Damber JE, Stadler WM, Hansen M, Edenbrandt L, Forsberg G, Nordle Ö, Pili R, Morris MJ. Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC). Urologic Oncology. 32: 1308-16. PMID 25240761 DOI: 10.1016/J.Urolonc.2014.08.006 |
0.375 |
|
| 2014 |
Pili R, Carducci M, Brown P, Hurwitz H. An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer. Investigational New Drugs. 32: 1258-68. PMID 25152243 DOI: 10.1007/S10637-014-0147-9 |
0.365 |
|
| 2014 |
Ku S, Lasorsa E, Adelaiye R, Ramakrishnan S, Ellis L, Pili R. Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer. Plos One. 9: e103680. PMID 25072314 DOI: 10.1371/Journal.Pone.0103680 |
0.629 |
|
| 2014 |
Kato Y, Yoshino I, Egusa C, Maeda T, Pili R, Tsuboi R. Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells. Journal of Dermatological Science. 75: 140-7. PMID 24866536 DOI: 10.1016/J.Jdermsci.2014.04.014 |
0.378 |
|
| 2014 |
Tracz A, Mastri M, Lee CR, Pili R, Ebos JM. Modeling spontaneous metastatic renal cell carcinoma (mRCC) in mice following nephrectomy. Journal of Visualized Experiments : Jove. PMID 24836396 DOI: 10.3791/51485 |
0.393 |
|
| 2014 |
Hanzly M, Aboumohamed A, Yarlagadda N, Creighton T, Digiorgio L, Fredrick A, Rao G, Mehedint D, George S, Attwood K, Kauffman E, Narashima D, Khushalani NI, Pili R, Schwaab T. High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience. Urology. 83: 1129-34. PMID 24767525 DOI: 10.1200/Jco.2013.31.15_Suppl.E15604 |
0.382 |
|
| 2014 |
Gupta N, Al Ustwani O, Shen L, Pili R. Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer. Oncotargets and Therapy. 7: 223-34. PMID 24600234 DOI: 10.2147/Ott.S53524 |
0.381 |
|
| 2014 |
Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, ... ... Pili R, et al. Kidney cancer, version 2.2014. Journal of the National Comprehensive Cancer Network : Jnccn. 12: 175-82. PMID 24586079 DOI: 10.6004/Jnccn.2014.0018 |
0.382 |
|
| 2014 |
Keizman D, Gottfried M, Ish-Shalom M, Maimon N, Peer A, Neumann A, Hammers H, Eisenberger MA, Sinibaldi V, Pili R, Hayat H, Kovel S, Sella A, Boursi B, Weitzen R, et al. Active smokingmay negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treatedwith sunitinib Oncologist. 19: 51-60. PMID 24309979 DOI: 10.1634/Theoncologist.2012-0335 |
0.375 |
|
| 2014 |
Buck MJ, Raaijmakers LM, Ramakrishnan S, Wang D, Valiyaparambil S, Liu S, Nowak NJ, Pili R. Alterations in chromatin accessibility and DNA methylation in clear cell renal cell carcinoma. Oncogene. 33: 4961-5. PMID 24186201 DOI: 10.1038/Onc.2013.455 |
0.574 |
|
| 2014 |
Gupta N, Zubair F, Anwar S, Wang K, Pili R, Satchidanand Y. Current Trend of Palliative Care Clinic Referrals in Patients with Gastrointestinal (GI) Cancer: Retrospective Analysis at an American Comprehensive Cancer Institute American Journal of Gastroenterology. 109: S199. DOI: 10.14309/00000434-201410002-00687 |
0.314 |
|
| 2014 |
Pili R. A phase II randomized, open label study of sipuleucel-T versus sipuleucel-T and tasquinimod in patients with metastatic castrate-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 32: TPS5110-TPS5110. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps5110 |
0.438 |
|
| 2014 |
Gupta N, Hatoum H, Al Ustwani O, Danchaivijitr P, Wang K, Pili R. Meta-analysis of aprepitant combination regimens (ACR) for prevention of chemotherapy-induced nausea and vomiting (CINV) in adults. Journal of Clinical Oncology. 32: e20622-e20622. DOI: 10.1200/Jco.2014.32.15_Suppl.E20622 |
0.317 |
|
| 2014 |
Pili R, Pal SK, George S, Voortman J, Danchaivijitr P, Adelaiye R, Webb N, Poslinski D, Groman A, Hutson A, Verheul HM. Phase I study of dalteparin in combination with sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology. 32: e15607-e15607. DOI: 10.1200/Jco.2014.32.15_Suppl.E15607 |
0.429 |
|
| 2014 |
Wentink MQ, Broxterman HJ, Gruijl TDd, Pili R, Vliet HJvd, Griffioen AW, Verheul HMW. Abstract 908: Development of a cell proliferation assay to be used as a read-out system for determining thein vivopotency of bevacizumab in neutralizing the biological activity of VEGF in cancer patients Cancer Research. 74: 908-908. DOI: 10.1158/1538-7445.Am2014-908 |
0.382 |
|
| 2014 |
Chintala S, Nguyen H, Ramakrishnan S, Ku S, Ciamporcero E, Miles KM, Pili R. Abstract 686: Regulation of intracellular sequestration of sunitinib by cystine transporter xCT in renal cancer Cancer Research. 74: 686-686. DOI: 10.1158/1538-7445.Am2014-686 |
0.618 |
|
| 2014 |
Ramakrishnan S, Ku S, Swetzig W, Conroy D, Shen L, Chintala S, Sotomayor P, Miles KM, Adelaiye R, Ciamporcero E, Orillion A, Ellis L, Das G, Pili R. Abstract 4061: Evidence for hdac6 and er-α association in a subset of clear cell renal cell carcinoma Cancer Research. 74: 4061-4061. DOI: 10.1158/1538-7445.Am2014-4061 |
0.6 |
|
| 2014 |
Ciamporcero ES, Shen H, Chintala S, Ramakrishnan S, Ku SY, Miles KM, Pizzimenti S, Johnson C, Zhang J, Barrera G, Pili R. Abstract 3754: Hippo pathway effector Yes-associated protein and cisplatin resistance in transitional cell carcinoma of the bladder Cancer Research. 74: 3754-3754. DOI: 10.1158/1538-7445.Am2014-3754 |
0.626 |
|
| 2014 |
Adelaiye R, Miles KM, Ciamporcero E, Conroy D, Ramakrishnan S, Orillion A, Ku SY, Elbanna M, shen L, Chintala S, Pili R. Abstract 1375: Epigenetic changes associated with resistance to sunitinib in human clear cell renal cell carcinoma models Cancer Research. 74: 1375-1375. DOI: 10.1158/1538-7445.Am2014-1375 |
0.632 |
|
| 2014 |
Orillion A, Miles KM, Shen L, Adelaiye R, Ciamporcero E, Ramakrishnan S, Ku SY, Elbanna M, Chintala S, Pili R. Abstract 1013: Angiopoietin 1/2 inhibition impairs tumor growth in an orthotopic model of renal cell carcinoma Cancer Research. 74: 1013-1013. DOI: 10.1158/1538-7445.Am2014-1013 |
0.64 |
|
| 2014 |
Taplin M, Chi K, Chu F, Cochran J, Edenfield W, Antonarakis E, Emmenegger U, Heath E, Hussain A, Njar V, Koletsky A, Lipsitz D, Nordquist L, Pili R, Rettig M, et al. 4 Activity of galeterone in castrate-resistant prostate cancer (CRPC) with C-terminal AR loss: Results from ARMOR2 European Journal of Cancer. 50: 8. DOI: 10.1016/S0959-8049(14)70130-3 |
0.346 |
|
| 2014 |
Raymond E, Dalgleish A, Damber JE, Smith M, Pili R. Mechanisms of action of tasquinimod on the tumour microenvironment Cancer Chemotherapy and Pharmacology. 73: 1-8. DOI: 10.1007/S00280-013-2321-8 |
0.385 |
|
| 2013 |
Ish-Shalom M, Maimon N, Gottfried M, Pili R, Hammers HJ, Eisenberger MA, Sinibaldi VJ, Boursi B, Weitzen R, Hayat H, Peer A, Neumann A, Kovel S, Sella A, Mermershtain W, et al. Is there a "trial effect" on outcome of patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 453. PMID 28137062 DOI: 10.1200/Jco.2013.31.6_Suppl.453 |
0.337 |
|
| 2013 |
Ish-Shalom M, Maimon N, Gottfried M, Pili R, Hammers HJ, Eisenberger MA, Sinibaldi VJ, Boursi B, Weitzen R, Hayat H, Peer A, Neumann A, Kovel S, Sella A, Mermershtain W, et al. Are there geographic differences in the outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (su)? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 458. PMID 28137045 DOI: 10.1200/Jco.2013.31.15_Suppl.E15598 |
0.328 |
|
| 2013 |
Ish-Shalom M, Maimon N, Gottfried M, Boursi B, Leibowitz-Amit R, Berger R, Neumann A, Kovel S, Sella A, Pili R, Hammers HJ, Sinibaldi VJ, Carducci MA, Eisenberger MA, Keizman D. Comparison of abiraterone acetate (Abi) versus ketoconazole (Keto) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel (D). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 146. PMID 28136875 DOI: 10.1200/Jco.2013.31.15_Suppl.E16068 |
0.381 |
|
| 2013 |
Ish-Shalom M, Maimon N, Gottfried M, Roubinov K, Pili R, Sinibaldi VJ, Hammers HJ, Carducci MA, Eisenberger MA, Mermershtain W. Influence of concurrent medications on PSA doubling time (PSADT) in patients (pts) with nonmetastatic biochemically relapsed prostate cancer (BRPC M0) after local therapy (tx). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 160. PMID 28136717 DOI: 10.1200/Jco.2013.31.15_Suppl.E16051 |
0.324 |
|
| 2013 |
Fontana L, Adelaiye RM, Rastelli AL, Miles KM, Ciamporcero E, Longo VD, Nguyen H, Vessella R, Pili R. Dietary protein restriction inhibits tumor growth in human xenograft models. Oncotarget. 4: 2451-61. PMID 24353195 DOI: 10.18632/Oncotarget.1586 |
0.397 |
|
| 2013 |
Armstrong AJ, Häggman M, Stadler WM, Gingrich JR, Assikis V, Polikoff J, Damber JE, Belkoff L, Nordle Ö, Forsberg G, Carducci MA, Pili R. Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6891-901. PMID 24255071 DOI: 10.1158/1078-0432.Ccr-13-1581 |
0.385 |
|
| 2013 |
Ellis L, Ku SY, Ramakrishnan S, Lasorsa E, Azabdaftari G, Godoy A, Pili R. Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer. Oncotarget. 4: 2225-36. PMID 24163230 DOI: 10.18632/Oncotarget.1314 |
0.61 |
|
| 2013 |
Rehman S, Crane A, Din R, Raza SJ, Shi Y, Wilding G, Levine EG, George S, Pili R, Trump DL, Guru KA. Understanding avoidance, refusal, and abandonment of chemotherapy before and after cystectomy for bladder cancer. Urology. 82: 1370-5. PMID 24125689 DOI: 10.1016/J.Urology.2013.07.055 |
0.327 |
|
| 2013 |
Batty N, Yarlagadda N, Pili R. Major response to cyclophosphamide and prednisone in recurrent castration-resistant prostate cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 11: 911-5. PMID 23946170 DOI: 10.6004/Jnccn.2013.0112 |
0.386 |
|
| 2013 |
Ramakrishnan S, Ellis L, Pili R. Histone modifications: implications in renal cell carcinoma. Epigenomics. 5: 453-62. PMID 23895657 DOI: 10.2217/Epi.13.40 |
0.566 |
|
| 2013 |
Pili R, Qin R, Flynn PJ, Picus J, Millward M, Ho WM, Pitot H, Tan W, Miles KM, Erlichman C, Vaishampayan U. A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clinical Genitourinary Cancer. 11: 477-83. PMID 23891158 DOI: 10.1016/J.Clgc.2013.05.005 |
0.438 |
|
| 2013 |
Ramakrishnan S, Pili R. Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma. Cancer Journal (Sudbury, Mass.). 19: 333-40. PMID 23867515 DOI: 10.1097/Ppo.0B013E3182A09E07 |
0.572 |
|
| 2013 |
Chatterjee S, Alsaeedi N, Hou J, Bandaru VV, Wu L, Halushka MK, Pili R, Ndikuyeze G, Haughey NJ. Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model. Plos One. 8: e63726. PMID 23671696 DOI: 10.1371/Journal.Pone.0063726 |
0.438 |
|
| 2013 |
George S, Pili R. Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancer. Current Oncology Reports. 15: 65-8. PMID 23334511 DOI: 10.1007/S11912-013-0295-7 |
0.423 |
|
| 2013 |
Berger R, Ish-Shalom M, Maimon N, Gottfried M, Pili R, Hammers HJ, Eisenberger MA, Sinibaldi VJ, Boursi B, Weitzen R, Hayat H, Peer A, Neumann A, Kovel S, Sella A, et al. Comparison between the outcome of metastatic RCC patients treated with sunitinib as part of clinical trials and matched nonparticipants receiving sutent as standard therapy. Journal of Clinical Oncology. 31: e15597-e15597. DOI: 10.1200/Jco.2013.31.15_Suppl.E15597 |
0.341 |
|
| 2013 |
Armstrong AJ, Kaboteh R, Carducci MA, Damber J, Stadler WM, Mats H, Edenbrandt L, Forsberg G, Nordle O, Pili R, Morris MJ. Association of bone scan index (BSI) with prognostic biomarkers and survival in men with metastatic castration-resistant prostate cancer (mCRPC) enrolled in a prospective randomized controlled trial of tasquinimod. Journal of Clinical Oncology. 31: 5081-5081. DOI: 10.1200/Jco.2013.31.15_Suppl.5081 |
0.312 |
|
| 2013 |
Pili R, Adelaiye R, Miles KM, Ciamporcero E, Sotomayor P, Bjarnason GA. Overcoming sunitinib-induced resistance by dose escalation in renal cell carcinoma: Evidence in animal models and patients. Journal of Clinical Oncology. 31: 4582-4582. DOI: 10.1200/Jco.2013.31.15_Suppl.4582 |
0.425 |
|
| 2013 |
Shen L, Miles KM, Ciesielski M, Ellis L, Fenstermaker R, Pili R. Abstract B91: Tasquinimod targets immuno-suppressive myeloid cell populations and enhances immunotherapy in murine prostate cancer models. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-B91 |
0.467 |
|
| 2013 |
Adelaiye RM, Miles KM, Ciamporcero E, Nguyen H, Vessella R, Fontana L, Pili R. Abstract 4859: Tumor growth inhibition and epigenetic changes following protein diet restriction in a human prostate cancer model. Cancer Research. 73: 4859-4859. DOI: 10.1158/1538-7445.Am2013-4859 |
0.346 |
|
| 2013 |
Shen L, Ciesielski M, Miles KM, Fenstermaker R, Pili R. Abstract 4746: Modulation of suppressive myeloid populations by tasquinimod. Cancer Research. 73: 4746-4746. DOI: 10.1158/1538-7445.Am2013-4746 |
0.462 |
|
| 2013 |
Ramakrishnan S, Sotomayor P, Ellis L, Chintala S, Pili R. Abstract 2987: VHL dependent and independent regulation of HDAC expression and activity in renal cell carcinomas. Cancer Research. 73: 2987-2987. DOI: 10.1158/1538-7445.Am2013-2987 |
0.625 |
|
| 2013 |
Ciamporcero ES, Miles KM, Adelaiye R, Pizzimenti S, Barrera G, Pili R. Abstract 1618: Combination of axitinib and crizotinib in renal cell carcinoma models. Cancer Research. 73: 1618-1618. DOI: 10.1158/1538-7445.Am2013-1618 |
0.469 |
|
| 2013 |
Gotink KJ, Pili R, Honeywell RJ, Griffioen AW, Peters GJ, Broxterman HJ, Verheul HM. Abstract 1613:In vitroacquired tumor cell resistance to sunitinib contributes to anin vivoresistant phenotype. Cancer Research. 73: 1613-1613. DOI: 10.1158/1538-7445.Am2013-1613 |
0.375 |
|
| 2013 |
Ku S, Pili R, Ellis L. Abstract 1008: Concomitant HDAC and PI3K-AKT pathway inhibition as a new therapeutic strategy for prostate cancer. Cancer Research. 73: 1008-1008. DOI: 10.1158/1538-7445.Am2013-1008 |
0.415 |
|
| 2013 |
Pili R, Kauffman E, Rodriguez R. Cancer of the Kidney Abeloff's Clinical Oncology: Fifth Edition. 1416-1444.e5. DOI: 10.1016/B978-1-4557-2865-7.00082-5 |
0.332 |
|
| 2012 |
Choi KS, Miecznikowski JC, Pili R, Kazim AL. The lipid metabolome of kidney cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 16. PMID 28142458 DOI: 10.1200/Jco.2012.30.30_Suppl.16 |
0.324 |
|
| 2012 |
Keizman D, Ish-Shalom M, Taksey JD, Pili R, Hammers HJ, Eisenberger MA, Boursi B, Berger R, Maimon N, Gottfried M, Hayat H, Peer A, Kovel S, Sella A, Carducci MA. Effect of bisphosphonates (Bis) combined with sunitinib (Su) on the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 379. PMID 27968163 DOI: 10.1200/Jco.2012.30.5_Suppl.379 |
0.337 |
|
| 2012 |
Kotowski AS, Stegemann A, Rehman S, Attwood K, Levine EG, Guru K, Trump DL, Pili R. A single-center experience of chemotherapy for muscle-invasive bladder cancer after radical cystectomy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 318. PMID 27968059 DOI: 10.1200/Jco.2012.30.5_Suppl.318 |
0.317 |
|
| 2012 |
Keizman D, Ish-Shalom M, Taksey JD, Pili R, Hammers HJ, Eisenberger MA, Boursi B, Berger R, Maimon N, Gottfried M, Hayat H, Peer A, Kovel S, Sella A, Carducci MA. Influence of risk factors for renal cell carcinoma (RCC) on outcome of patients (pts) with metastatic disease treated with sunitinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 437. PMID 27968055 DOI: 10.1200/Jco.2012.30.5_Suppl.437 |
0.346 |
|
| 2012 |
Shen L, Pili R. Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy. Oncoimmunology. 1: 948-950. PMID 23162767 DOI: 10.4161/Onci.20306 |
0.362 |
|
| 2012 |
Keizman D, Gottfried M, Ish-Shalom M, Maimon N, Peer A, Neumann A, Rosenbaum E, Kovel S, Pili R, Sinibaldi V, Carducci MA, Hammers H, Eisenberger MA, Sella A. Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: Association with outcome and predictive nomogram Oncologist. 17: 1508-1514. PMID 22971522 DOI: 10.1634/Theoncologist.2012-0125 |
0.388 |
|
| 2012 |
Minelli R, Cavalli R, Ellis L, Pettazzoni P, Trotta F, Ciamporcero E, Barrera G, Fantozzi R, Dianzani C, Pili R. Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 47: 686-94. PMID 22917641 DOI: 10.1016/J.Ejps.2012.08.003 |
0.424 |
|
| 2012 |
Welti JC, Powles T, Foo S, Gourlaouen M, Preece N, Foster J, Frentzas S, Bird D, Sharpe K, van Weverwijk A, Robertson D, Soffe J, Erler JT, Pili R, Springer CJ, et al. Contrasting effects of sunitinib within in vivo models of metastasis. Angiogenesis. 15: 623-41. PMID 22843200 DOI: 10.1007/S10456-012-9291-Z |
0.352 |
|
| 2012 |
Chintala S, Najrana T, Toth K, Cao S, Durrani FA, Pili R, Rustum YM. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition. Bmc Cancer. 12: 293. PMID 22804960 DOI: 10.1186/1471-2407-12-293 |
0.409 |
|
| 2012 |
Tolcher AW, Chi KN, Shore ND, Pili R, Molina A, Acharya M, Kheoh T, Jiao JJ, Gonzalez M, Trinh A, Pankras C, Tran N. Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology. 70: 305-13. PMID 22752297 DOI: 10.1007/S00280-012-1916-9 |
0.399 |
|
| 2012 |
Ebos JM, Pili R. Mind the gap: potential for rebounds during antiangiogenic treatment breaks. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3719-21. PMID 22679177 DOI: 10.1158/1078-0432.Ccr-12-1459 |
0.401 |
|
| 2012 |
Morris MJ, Eisenberger MA, Pili R, Denmeade SR, Rathkopf D, Slovin SF, Farrelly J, Chudow JJ, Vincent M, Scher HI, Carducci MA. A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 23: 2714-9. PMID 22553195 DOI: 10.1093/Annonc/Mds078 |
0.36 |
|
| 2012 |
Keizman D, Ish-Shalom M, Pili R, Hammers H, Eisenberger MA, Sinibaldi V, Boursi B, Maimon N, Gottfried M, Hayat H, Peer A, Kovel S, Sella A, Berger R, Carducci MA. Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma European Journal of Cancer. 48: 1031-1037. PMID 22409947 DOI: 10.1016/J.Ejca.2012.02.050 |
0.332 |
|
| 2012 |
Shen L, Ciesielski M, Ramakrishnan S, Miles KM, Ellis L, Sotomayor P, Shrikant P, Fenstermaker R, Pili R. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. Plos One. 7: e30815. PMID 22303460 DOI: 10.1371/Journal.Pone.0030815 |
0.627 |
|
| 2012 |
Pili R, Salumbides B, Zhao M, Altiok S, Qian D, Zwiebel J, Carducci MA, Rudek MA. Phase i study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours British Journal of Cancer. 106: 77-84. PMID 22134508 DOI: 10.1038/Bjc.2011.527 |
0.358 |
|
| 2012 |
Ellis L, Shah P, Hammers H, Lehet K, Sotomayor P, Azabdaftari G, Seshadri M, Pili R. Vascular disruption in combination with mTOR inhibition in renal cell carcinoma. Molecular Cancer Therapeutics. 11: 383-92. PMID 22084164 DOI: 10.1158/1535-7163.Mct-11-0748 |
0.449 |
|
| 2012 |
Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R, Hammers H, Carducci MA. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. European Journal of Cancer (Oxford, England : 1990). 48: 202-8. PMID 22018713 DOI: 10.1016/J.Ejca.2011.09.001 |
0.394 |
|
| 2012 |
Ellis L, Lehet K, Ramakrishnan S, Adelaiye R, Pili R. Development of a castrate resistant transplant tumor model of prostate cancer. The Prostate. 72: 587-91. PMID 21796655 DOI: 10.1002/Pros.21465 |
0.61 |
|
| 2012 |
Bruce JY, Eickhoff J, Pili R, Logan T, Carducci M, Arnott J, Treston A, Wilding G, Liu G. A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate. Investigational New Drugs. 30: 794-802. PMID 21174224 DOI: 10.1007/S10637-010-9618-9 |
0.428 |
|
| 2012 |
Pili R, Shen L, George S, Hammers H, Sandecki A, Collins C, Espinoza-Delgado I, Carducci MA. Phase I/II study of high-dose interleukin 2, aldesleukin, in combination with the histone deacetylase inhibitor entinostat in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology. 30: TPS4687-TPS4687. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps4687 |
0.409 |
|
| 2012 |
Kossoff E, Batty N, Ceacareanu AC, Attwood K, Miller D, Rabey J, Lee C, Ahmad A, Ebos JM, Schwaab T, George S, Pili R. Evaluation of parameters for treatment duration of sunitinib in metastatic renal cell carcinoma. Journal of Clinical Oncology. 30: e15042-e15042. DOI: 10.1200/Jco.2012.30.15_Suppl.E15042 |
0.323 |
|
| 2012 |
Montgomery RB, Eisenberger MA, Rettig M, Chu F, Pili R, Stephenson J, Vogelzang NJ, Morrison J, Taplin M. Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer (CRPC). Journal of Clinical Oncology. 30: 4665-4665. DOI: 10.1200/Jco.2012.30.15_Suppl.4665 |
0.36 |
|
| 2012 |
Armstrong AJ, Haggman M, Stadler WM, Gingrich JR, Assikis VJ, Polikoff J, Denmeade SR, George DJ, Andreou C, Clark WR, Sieber P, Agajanian R, Belkoff L, Damber J, Nordle O, ... ... Pili R, et al. Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: Results of long-term follow-up of a randomized phase II placebo-controlled trial. Journal of Clinical Oncology. 30: 4550-4550. DOI: 10.1200/Jco.2012.30.15_Suppl.4550 |
0.342 |
|
| 2012 |
Ellis L, Ramakrishnan S, Ku S, Pili R. Abstract C7: Targeting the androgen receptor with novel combination therapeutic strategies in metastatic/castrate-resistant prostate cancer Cancer Research. 72: C7-C7. DOI: 10.1158/1538-7445.Prca2012-C7 |
0.617 |
|
| 2012 |
Ellis L, Adelaiye R, Ku S, Godoy A, Pili R. Abstract B5: Epigenetic modification of AR in PC3 cells negatively regulates mTORC1/2 activity Cancer Research. 72: B5-B5. DOI: 10.1158/1538-7445.Prca2012-B5 |
0.408 |
|
| 2012 |
Taplin M, Chu F, Morrison JP, Pili R, Rettig MB, Stephenson J, Vogelzang NJ, Montgomery RB. Abstract CT-07: ARMOR1: Safety of galeterone (TOK-001) in a Phase 1 clinical trial in chemotherapy naïve patients with castration resistant prostate cancer (CRPC) Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Ct-07 |
0.43 |
|
| 2012 |
Ramakrishnan S, Sotomayor P, Lehet K, Pili R. Abstract 5016: Epigenetics in renal cell carcinoma Cancer Research. 72: 5016-5016. DOI: 10.1158/1538-7445.Am2012-5016 |
0.621 |
|
| 2012 |
Sotomayor P, Godoy A, Gross K, Smith G, Pili R. Abstract 4380: Effect of sunitinib on endothelial-pericyte cell interaction Cancer Research. 72: 4380-4380. DOI: 10.1158/1538-7445.Am2012-4380 |
0.37 |
|
| 2012 |
Adelaiye RM, Ellis L, Pili R. Abstract 2766: Targeting heat shock proteins: Novel strategies for treating prostate cancer Cancer Research. 72: 2766-2766. DOI: 10.1158/1538-7445.Am2012-2766 |
0.44 |
|
| 2012 |
Miles KM, Gillard B, Kuhnert F, Thurston G, Lalani AS, Pili R. Abstract 2329: Anti-tumor efficacy of Dll4 blockade in combination with sunitinib or aflibercept in primary human renal cell carcinoma models Cancer Research. 72: 2329-2329. DOI: 10.1158/1538-7445.Am2012-2329 |
0.421 |
|
| 2012 |
Shen L, Ciesielski M, Miles KM, Ellis L, Fenstermaker R, Pili R. Abstract 1551: Targeting myeloid derived suppressor cells as novel strategy to enhance immunotherapy in murine prostate cancer models Cancer Research. 72: 1551-1551. DOI: 10.1158/1538-7445.Am2012-1551 |
0.458 |
|
| 2012 |
Gotink KJ, Broxterman HJ, Haas RRd, Rovithi MN, Pili R, Verheul HM. Abstract 1374: Cross-resistance and sensitivity of sunitinib resistant tumor cells Cancer Research. 72: 1374-1374. DOI: 10.1158/1538-7445.Am2012-1374 |
0.407 |
|
| 2012 |
Carducci M, Armstrong A, Häggman M, Stadler W, Gingrich J, Assikis V, Forsberg G, Olsson A, Nordle Ö, Pili R. Tasquinimod Mechanism of Action Biomarkers: Correlation with PFS and Survival in Men with Metastatic Castrate Resistant Prostate Cancer Treated in a Randomized Phase 2 Trial Annals of Oncology. 23: ix303. DOI: 10.1016/S0923-7534(20)33477-3 |
0.378 |
|
| 2012 |
Ramakrishnan S, Pili R. Epigenetic targeting and histone deacetylase inhibition in RCC Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets. 2147483647: 193-211. DOI: 10.1007/978-1-4614-2400-0_9 |
0.549 |
|
| 2011 |
Huang P, Carducci MA, Eisenberger MA, Pili R, Kim JJ, Antonarakis ES, Hammers HJ, Keizman D. The association of pretreatment (pre-tx) neutrophil to lymphocyte ratio (NLR) with outcome of sunitinib tx in patients (pts) with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4621. PMID 28023968 DOI: 10.1200/Jco.2011.29.15_Suppl.4621 |
0.353 |
|
| 2011 |
Goldman JW, Gordon MS, Hurwitz H, Pili R, Mendelson DS, Adams BJ, Alvarez D, Seon BK, Theuer CP, Leigh BR, Rosen LS. A phase I study of TRC105 (anti-CD105 antibody) in patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3073. PMID 28022536 DOI: 10.1200/Jco.2011.29.15_Suppl.3073 |
0.328 |
|
| 2011 |
Armstrong AJ, Haggman M, Stadler WM, Gingrich JR, Assikis VJ, Nordle O, Forsberg G, Carducci MA, Pili R. Phase II study of tasquinimod in chemotherapy-naive patients with metastatic castrate-resistant prostate cancer (CRPC): Safety and efficacy analysis including subgroups. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 126. PMID 27968532 DOI: 10.1200/Jco.2011.29.7_Suppl.126 |
0.41 |
|
| 2011 |
Pili R, Qin R, Flynn PJ, Picus J, Millward M, Ho WM, Pitot HC, Tan W, Erlichman C, Vaishampayan UN. MC0553: A phase II safety and efficacy study with the VEGF receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 259. PMID 27968513 DOI: 10.1200/Jco.2011.29.7_Suppl.259 |
0.404 |
|
| 2011 |
Keizman D, Huang P, Eisenberger MA, Pili R, Kim JJ, Hammers HJ, Carducci MA. Effect of angiotenstin system inhibitors (ASIs) on the outcome of sunitinib treatment (tx) in patients (pts) with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 317. PMID 27968318 DOI: 10.1200/Jco.2011.29.7_Suppl.317 |
0.402 |
|
| 2011 |
Tamaskar I, Dhillon J, Pili R. Resistance to angiogenesis inhibitors in renal cell carcinoma. Clinical Advances in Hematology & Oncology : H&O. 9: 101-10. PMID 22173604 |
0.304 |
|
| 2011 |
Ellis L, Lehet K, Ramakrishnan S, Adelaiye R, Miles KM, Wang D, Liu S, Atadja P, Carducci MA, Pili R. Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression. Plos One. 6: e27178. PMID 22087262 DOI: 10.1371/Journal.Pone.0027178 |
0.64 |
|
| 2011 |
Gotink KJ, Broxterman HJ, Labots M, de Haas RR, Dekker H, Honeywell RJ, Rudek MA, Beerepoot LV, Musters RJ, Jansen G, Griffioen AW, Assaraf YG, Pili R, Peters GJ, Verheul HM. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 7337-46. PMID 21980135 DOI: 10.1158/1078-0432.Ccr-11-1667 |
0.328 |
|
| 2011 |
Pili R, Häggman M, Stadler WM, Gingrich JR, Assikis VJ, Björk A, Nordle O, Forsberg G, Carducci MA, Armstrong AJ. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4022-8. PMID 21931019 DOI: 10.1200/Jco.2011.35.6295 |
0.386 |
|
| 2011 |
George S, Pili R, Carducci MA, Kim JJ. Role of immunotherapy for renal cell cancer in 2011. Journal of the National Comprehensive Cancer Network : Jnccn. 9: 1011-8. PMID 21917625 DOI: 10.6004/Jnccn.2011.0085 |
0.416 |
|
| 2011 |
Schwaab T, Pili R. Provenge: combating prostate cancer with a vengeance? Expert Review of Vaccines. 10: 1113-4. PMID 21854304 DOI: 10.1586/Erv.11.85 |
0.345 |
|
| 2011 |
Pettazzoni P, Ciamporcero E, Medana C, Pizzimenti S, Dal Bello F, Minero VG, Toaldo C, Minelli R, Uchida K, Dianzani MU, Pili R, Barrera G. Nuclear factor erythroid 2-related factor-2 activity controls 4-hydroxynonenal metabolism and activity in prostate cancer cells. Free Radical Biology & Medicine. 51: 1610-8. PMID 21816220 DOI: 10.1016/J.Freeradbiomed.2011.07.009 |
0.401 |
|
| 2011 |
O'Malley RL, Brewer KA, Hayn MH, Kim HL, Underwood W, Pili R, Schwaab T. Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease related factors responsible? Urology. 78: 595-600. PMID 21777963 DOI: 10.1016/J.Urology.2011.03.009 |
0.34 |
|
| 2011 |
Keizman D, Huang P, Eisenberger MA, Pili R, Kim JJ, Antonarakis ES, Hammers H, Carducci MA. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. European Journal of Cancer (Oxford, England : 1990). 47: 1955-61. PMID 21600760 DOI: 10.1016/J.Ejca.2011.04.019 |
0.364 |
|
| 2011 |
Hudes GR, Carducci MA, Choueiri TK, Esper P, Jonasch E, Kumar R, Margolin KA, Michaelson MD, Motzer RJ, Pili R, Roethke S, Srinivas S. NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. Journal of the National Comprehensive Cancer Network : Jnccn. 9: S1-29. PMID 21335444 DOI: 10.6004/Jnccn.2011.0124 |
0.329 |
|
| 2011 |
Pettazzoni P, Pizzimenti S, Toaldo C, Sotomayor P, Tagliavacca L, Liu S, Wang D, Minelli R, Ellis L, Atadja P, Ciamporcero E, Dianzani MU, Barrera G, Pili R. Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells. Free Radical Biology & Medicine. 50: 313-22. PMID 21078383 DOI: 10.1016/J.Freeradbiomed.2010.11.011 |
0.444 |
|
| 2011 |
Harrison MR, Hahn NM, Pili R, Oh WK, Hammers H, Sweeney C, Kim K, Perlman S, Arnott J, Sidor C, Wilding G, Liu G. A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Investigational New Drugs. 29: 1465-74. PMID 20499131 DOI: 10.1007/S10637-010-9455-X |
0.406 |
|
| 2011 |
Resta LP, Pili R, Eisenberger MA, Spitz A, King S, Porter J, Franke A, Boinpally R, Carducci MA, Sweeney CJ. A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. Cancer Chemotherapy and Pharmacology. 67: 431-8. PMID 20445979 DOI: 10.1007/S00280-010-1328-7 |
0.363 |
|
| 2011 |
Minelli R, Cavalli R, Fantozzi R, Dianzani C, Pettazzoni P, Ellis L, Shen L, Pili R. Abstract 4431: Antitumor activity of nanosponge-encapsulated camptotechin in human prostate tumors Cancer Research. 71: 4431-4431. DOI: 10.1158/1538-7445.Am2011-4431 |
0.452 |
|
| 2011 |
Paesante S, Miles MK, Nguyen H, Vessella R, Pili R. Abstract 3504: Targeting the Akt pathway and HDAC signaling in prostate cancer Cancer Research. 71: 3504-3504. DOI: 10.1158/1538-7445.Am2011-3504 |
0.489 |
|
| 2011 |
Shen L, Ciesielski M, Ellis L, Fenstermaker R, Pili R. Abstract 1792: Selective class I HDAC inhibitor SNDX-275 enhances anti-tumor survivin vaccine therapy by suppressing regulatory T cells in a model of prostate cancer Cancer Research. 71: 1792-1792. DOI: 10.1158/1538-7445.Am2011-1792 |
0.471 |
|
| 2011 |
Pili R, Chi K, Shore N, Papadopoulos K, Smith L, Beeram M, Molina A, Acharya M, Kheoh T, Jiao J, Gonzalez M, Pankras C, Trinh A, Tran N, Tolcher A. Abstract A194: A QT/QTc and multi-dose pharmacokinetic (PK) study of abiraterone acetate (AA) plus prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A194 |
0.366 |
|
| 2011 |
Ellis L, Lehet K, Ramakrishnan S, Miles K, Wang D, Liu S, Atadja P, Carducci M, Pili R. 7054 POSTER Concurrent Histone Deacetylase and Mammalian Target of Rapamycin Inhibition Attenuate Androgen Receptor and Hypoxia Signaling Associated With Alterations in MicroRNA Expression European Journal of Cancer. 47: S501. DOI: 10.1016/S0959-8049(11)72005-6 |
0.526 |
|
| 2010 |
Ellis L, Pili R. Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies. Pharmaceuticals (Basel, Switzerland). 3: 2411-2469. PMID 21151768 DOI: 10.3390/Ph3082441 |
0.39 |
|
| 2010 |
Keizman D, Zahurak M, Sinibaldi V, Carducci M, Denmeade S, Drake C, Pili R, Antonarakis ES, Hudock S, Eisenberger M. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5269-76. PMID 20978144 DOI: 10.1158/1078-0432.Ccr-10-1928 |
0.373 |
|
| 2010 |
Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, Jaspers J, Shah P, Ellis L, Shen L, Paesante S, Dykema K, Furge K, Teh BT, Netto G, Pili R. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Molecular Cancer Therapeutics. 9: 1525-35. PMID 20501804 DOI: 10.1158/1535-7163.Mct-09-1106 |
0.466 |
|
| 2010 |
Pili R, Rosenthal MA, Mainwaring PN, Van Hazel G, Srinivas S, Dreicer R, Goel S, Leach J, Wong S, Clingan P. Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2906-14. PMID 20460477 DOI: 10.1158/1078-0432.Ccr-09-3026 |
0.327 |
|
| 2010 |
Koskimaki JE, Karagiannis ED, Tang BC, Hammers H, Watkins DN, Pili R, Popel AS. Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model. Bmc Cancer. 10: 29. PMID 20122172 DOI: 10.1186/1471-2407-10-29 |
0.364 |
|
| 2010 |
Verheul HM, van Erp K, Homs MY, Yoon GS, van der Groep P, Rogers C, Hansel DE, Netto GJ, Pili R. The relationship of vascular endothelial growth factor and coagulation factor (fibrin and fibrinogen) expression in clear cell renal cell carcinoma. Urology. 75: 608-14. PMID 19683801 DOI: 10.1016/J.Urology.2009.05.075 |
0.396 |
|
| 2010 |
Keizman D, Sinibaldi VJ, Carducci MA, Denmeade SR, Drake CG, Pili R, Antonarakis ES, Hudock S, Zahurak M, Eisenberger MA. Phase I/II double-blinded randomized study to determine the tolerability and efficacy of two different doses of lenalidomide (Len) in biochemically relapsed prostate cancer (BRPC) (M0) patients (pts). Journal of Clinical Oncology. 28: 4554-4554. DOI: 10.1200/Jco.2010.28.15_Suppl.4554 |
0.365 |
|
| 2010 |
Pili R, Haggman M, Stadler WM, Gingrich JR, Assikis VJ, Björk A, Forsberg G, Carducci MA, Armstrong AJ. A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naïve patients with metastatic castrate-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 28: 4510-4510. DOI: 10.1200/Jco.2010.28.15_Suppl.4510 |
0.42 |
|
| 2010 |
Shen L, Pili R. Abstract 5437: The histone deacetylase (HDAC) inhibitor SNDX-275 enhances the antitumor effect of interleukin 2 (IL-2) by suppressing regulatory T cell gene expression and function Cancer Research. 70: 5437-5437. DOI: 10.1158/1538-7445.Am10-5437 |
0.391 |
|
| 2010 |
Hammers HJ, Verheul H, Salumbides B, Sharma R, Jaspers J, Rudek M, Netto G, Pili R. Abstract 388: Epithelial to mesenchymal transition is associated with acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study Cancer Research. 70: 388-388. DOI: 10.1158/1538-7445.Am10-388 |
0.482 |
|
| 2010 |
Schultz L, Albadine R, Hicks J, De Marzo A, Reuter V, Carducci M, Pili R, Argani P, Netto G. 202 MTOR PATHWAY IN PAPILLARY RENAL CELL CARCINOMA (PAPRCC): PROGNOSTIC ROLE AND POTENTIAL TARGET OF THERAPY Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.259 |
0.35 |
|
| 2010 |
Schultz L, Albadine R, Hicks J, De Marzo A, Reuter V, Carducci M, Pili R, Argani P, Netto G. 201 HIF 1 ALPHA AND PHOS S6 ARE INDEPENDENT PREDICTORS OF SURVIVAL IN CLEAR CELL RENAL CELL CARCINOMA (CCRCC) Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.258 |
0.333 |
|
| 2009 |
Sinibaldi VJ, Carducci MA, Moore-Cooper S, George B, Denmeade S, Drake CG, Walczak J, Pili R, Zahurak ML, Eisenberger MA. A randomized double blind phase I-II study to determine the tolerability/efficacy of two different doses of lenalidomide (L), CC- 5013, in biochemically relapsed (BR) prostate cancer (PC) patients (pts) (M0) after local treatment (LT). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5130. PMID 27964411 DOI: 10.1200/Jco.2009.27.15_Suppl.5130 |
0.36 |
|
| 2009 |
Salumbides BC, Lehet KM, Ndikuyeze G, Pili R. Pre-clinical models of renal carcinoma and their utility in drug development. Current Protocols in Pharmacology / Editorial Board, S.J. Enna (Editor-in-Chief) ... [Et Al.]. Unit 14.13. PMID 22294393 DOI: 10.1002/0471141755.Ph1413S47 |
0.421 |
|
| 2009 |
Tamaskar I, Pili R. Update on novel agents in renal cell carcinoma. Expert Review of Anticancer Therapy. 9: 1817-27. PMID 19954293 DOI: 10.1586/Era.09.157 |
0.407 |
|
| 2009 |
Bradley D, Rathkopf D, Dunn R, Stadler WM, Liu G, Smith DC, Pili R, Zwiebel J, Scher H, Hussain M. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): Trial results and interleukin-6 analysis: A study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago phase 2 consortium Cancer. 115: 5541-5549. PMID 19711464 DOI: 10.1002/Cncr.24597 |
0.395 |
|
| 2009 |
Vaughn DJ, Srinivas S, Stadler WM, Pili R, Petrylak D, Sternberg CN, Smith DC, Ringuette S, De Wit E, Pautret V, George C. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: Results of a large phase 2 study Cancer. 115: 4110-4117. PMID 19536904 DOI: 10.1002/Cncr.24460 |
0.339 |
|
| 2009 |
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3584-90. PMID 19487381 DOI: 10.1200/Jco.2008.20.1293 |
0.377 |
|
| 2009 |
Kolmakova A, Rajesh M, Zang D, Pili R, Chatterjee S. VEGF recruits lactosylceramide to induce endothelial cell adhesion molecule expression and angiogenesis in vitro and in vivo. Glycoconjugate Journal. 26: 547-58. PMID 19219548 DOI: 10.1007/S10719-008-9206-9 |
0.329 |
|
| 2009 |
Ellis L, Hammers H, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Letters. 280: 145-53. PMID 19111391 DOI: 10.1016/J.Canlet.2008.11.012 |
0.378 |
|
| 2009 |
Harrison MR, Pili R, Logan T, Wilding G, Eickhoff J, Sidor C, Staab M, Arnott J, Liu G. Phase II study of 2-methoxyestradiol NanoCrystal dispersion (2ME2) alone and in combination with sunitinib (SU) in patients with metastatic renal cell carcinoma (mRCC) progressing on SU. Journal of Clinical Oncology. 27. DOI: 10.1200/Jco.2009.27.15_Suppl.E16116 |
0.364 |
|
| 2008 |
Harrison MR, Hahn N, Pili R, Oh WK, Kim K, Wilding G, Sweeney CJ, Sidor C, Arnott J, Liu G. Phase II study of 2-methoxyestradiol (2ME2) NanoCrystal Dispersion (NCD) in patients with taxane-refractory, metastatic hormone-refractory prostate cancer (HRPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5173. PMID 27948238 DOI: 10.1200/Jco.2008.26.15_Suppl.5173 |
0.38 |
|
| 2008 |
Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, Harper F, Gaskins M, Pitot HC, Tan W, Ivy SP, Pili R, Carducci MA, Erlichman C, Liu G. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7940-6. PMID 19047126 DOI: 10.1158/1078-0432.Ccr-08-0221 |
0.391 |
|
| 2008 |
Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, Rey S, Hammers H, Chang D, Pili R, Dang CV, Liu JO, Semenza GL. Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth Proceedings of the National Academy of Sciences of the United States of America. 105: 19579-19586. PMID 19020076 DOI: 10.1073/Pnas.0809763105 |
0.398 |
|
| 2008 |
Rathkopf D, Carducci MA, Morris MJ, Slovin SF, Eisenberger MA, Pili R, Denmeade SR, Kelsen M, Curley T, Halter M, Collins C, Fleisher M, Heller G, Baker SD, Scher HI. Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2959-65. PMID 18565882 DOI: 10.1200/Jco.2007.15.1928 |
0.371 |
|
| 2008 |
Verheul HM, Salumbides B, Van Erp K, Hammers H, Qian DZ, Sanni T, Atadja P, Pili R. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 3589-97. PMID 18519793 DOI: 10.1158/1078-0432.Ccr-07-4306 |
0.342 |
|
| 2008 |
Siu LL, Pili R, Duran I, Messersmith WA, Chen EX, Sullivan R, MacLean M, King S, Brown S, Reid GK, Li Z, Kalita AM, Laille EJ, Besterman JM, Martell RE, et al. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1940-7. PMID 18421048 DOI: 10.1200/Jco.2007.14.5730 |
0.375 |
|
| 2008 |
Shen L, Pili R. Posttranscription regulation of prostate cancer growth. Cancer Journal (Sudbury, Mass.). 14: 46-53. PMID 18303483 DOI: 10.1097/Ppo.0B013E318162108A |
0.393 |
|
| 2008 |
Hammers HJ, Verheul H, Wilky B, Salumbides B, Holleran J, Egorin MJ, Lodge M, Wahl RL, Zwiebel JA, Carducci MA, Pili R. Phase I safety and pharmacokinetic/pharmacodynamic results of the histone deacetylase inhibitor vorinostat in combination with bevacizumab in patients with kidney cancer Journal of Clinical Oncology. 26: 16094-16094. DOI: 10.1200/Jco.2008.26.15_Suppl.16094 |
0.412 |
|
| 2007 |
Kachhap SK, Faith D, Qian DZ, Shabbeer S, Galloway NL, Pili R, Denmeade SR, DeMarzo AM, Carducci MA. The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin. Plos One. 2: e844. PMID 17786215 DOI: 10.1371/Journal.Pone.0000844 |
0.337 |
|
| 2007 |
Collins C, Carducci MA, Eisenberger MA, Isaacs JT, Partin AW, Pili R, Sinibaldi VJ, Walczak JS, Denmeade SR. Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint. Cancer Biology & Therapy. 6: 1360-7. PMID 17786033 DOI: 10.4161/Cbt.6.9.4541 |
0.382 |
|
| 2007 |
Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni TB, Salumbides BC, Van Erp K, Schulick R, Pili R. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 4538-46. PMID 17671140 DOI: 10.1158/1078-0432.Ccr-07-0014 |
0.397 |
|
| 2007 |
Verheul HM, Hammers H, van Erp K, Wei Y, Sanni T, Salumbides B, Qian DZ, Yancopoulos GD, Pili R. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 4201-8. PMID 17634549 DOI: 10.1158/1078-0432.Ccr-06-2553 |
0.385 |
|
| 2007 |
Qian DZ, Wei YF, Wang X, Kato Y, Cheng L, Pili R. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models. The Prostate. 67: 1182-93. PMID 17520666 DOI: 10.1002/Pros.20611 |
0.384 |
|
| 2007 |
Bajaj GK, Zhang Z, Garrett-Mayer E, Drew R, Sinibaldi V, Pili R, Denmeade SR, Carducci MA, Eisenberger MA, DeWeese TL. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology. 69: 526-31. PMID 17382158 DOI: 10.1016/J.Urology.2006.12.006 |
0.389 |
|
| 2007 |
Verheul HM, Qian DZ, Carducci MA, Pili R. Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs. Cancer Chemotherapy and Pharmacology. 60: 329-39. PMID 17256134 DOI: 10.1007/S00280-006-0379-2 |
0.326 |
|
| 2007 |
Kato Y, Salumbides BC, Wang XF, Qian DZ, Williams S, Wei Y, Sanni TB, Atadja P, Pili R. Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. Molecular Cancer Therapeutics. 6: 70-81. PMID 17237267 DOI: 10.1158/1535-7163.Mct-06-0125 |
0.409 |
|
| 2007 |
Pili R, Rosenthal M. Randomized phase II study of docetaxel with or without DMXAA (AS1404) in hormone-refractory metastatic prostate cancer (HRMPC) Journal of Clinical Oncology. 25: 5115-5115. DOI: 10.1200/Jco.2007.25.18_Suppl.5115 |
0.428 |
|
| 2007 |
Rathkopf DE, Carducci MA, Slovin S, Morris MJ, Kelsen M, Pili R, Denmeade SR, Eisenberger M, Scher HI. A phase II trial of rapid androgen cycling and docetaxel (Doc) in prostate cancer patients with a rising prostate-specific antigen (PSA) in the noncastrate state Journal of Clinical Oncology. 25: 5004-5004. DOI: 10.1200/Jco.2007.25.18_Suppl.5004 |
0.365 |
|
| 2007 |
Heath EI, Hillman D, Vaishampayan U, Sheng S, Sarkar FH, Gaskins M, Pitot HC, Tan W, Ivy P, Pili R. A phase II trial of 17-allylamino-17-demethoxygeldanamycin (17-AAG) in patients with hormone-refractory metastatic prostate cancer Journal of Clinical Oncology. 25: 15553-15553. DOI: 10.1200/Jco.2007.25.18_Suppl.15553 |
0.375 |
|
| 2007 |
Sinibaldi VJ, Carducci MA, DeWeese T, Weber J, Drew R, Moore-Cooper S, Denmeade S, Pili R, Walczak J, Sugar E, Eisenberger MA. Phase I trial of docetaxel (D) plus samarium153 (Sm 153) in patients (pts) with hormone refractory prostate cancer (HRPC) Journal of Clinical Oncology. 25: 15547-15547. DOI: 10.1200/Jco.2007.25.18_Suppl.15547 |
0.315 |
|
| 2007 |
Vaughn DJ, Srinivas S, Stadler WM, Pili R, Petrylak D, Marco SD, Smith DC, Nason S, Wit ED, George C. Phase II study of single-agent vinflunine in platinum-refractory transitional cell carcinoma of the urothelium (TCCU) Journal of Clinical Oncology. 25: 15543-15543. DOI: 10.1200/Jco.2007.25.18_Suppl.15543 |
0.321 |
|
| 2007 |
George C, Vaughn D, Petrylak D, Srinivas S, Pili R, Stadler W, De Marco S, Smith D, Nason S, DeWit E. 4534 POSTER Phase II study of single-agent vinflunine in platinum-refractory transitional cell carcinoma of the urothelium (TCCU) European Journal of Cancer Supplements. 5: 309. DOI: 10.1016/S1359-6349(07)71165-5 |
0.307 |
|
| 2006 |
Isaacs JT, Pili R, Qian DZ, Dalrymple SL, Garrison JB, Kyprianou N, Björk A, Olsson A, Leanderson T. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. The Prostate. 66: 1768-78. PMID 16955399 DOI: 10.1002/Pros.20509 |
0.374 |
|
| 2006 |
Sinibaldi VJ, Elza-Brown K, Schmidt J, Eisenberger MA, Rosenbaum E, Denmeade SR, Pili R, Walczak J, Baker SD, Zahurak M, Carducci MA. Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma American Journal of Clinical Oncology: Cancer Clinical Trials. 29: 395-398. PMID 16891869 DOI: 10.1097/01.Coc.0000225411.95479.B4 |
0.392 |
|
| 2006 |
Chong CR, Qian DZ, Pan F, Wei Y, Pili R, Sullivan DJ, Liu JO. Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target. Journal of Medicinal Chemistry. 49: 2677-80. PMID 16640327 DOI: 10.1021/Jm051225T |
0.345 |
|
| 2006 |
Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T, Atadja P, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 634-42. PMID 16428510 DOI: 10.1158/1078-0432.Ccr-05-1132 |
0.387 |
|
| 2006 |
Pili R, Rudek M, Altiok S, Qian D, Zhao M, Donehower R, Anderson A, Halter M, McFarland H, Zwiebel J, Carducci M. Phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor MS-275 in combination with 13-cis retinoic acid in patients with advanced solid tumors Journal of Clinical Oncology. 24: 3055-3055. DOI: 10.1200/Jco.2006.24.18_Suppl.3055 |
0.378 |
|
| 2006 |
Carducci M, Siu LL, Sullivan R, Maclean M, Kalita A, Chen EX, Pili R, Martell RE, Besterman J, Reid GK. Phase I study of isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 given as three-times weekly oral dose in patients (pts) with advanced solid tumors Journal of Clinical Oncology. 24: 3007-3007. DOI: 10.1200/Jco.2006.24.18_Suppl.3007 |
0.389 |
|
| 2006 |
Sinibaldi VJ, Carducci MA, Elza-Brown K, Rosenbaum E, Denmeade S, Pili R, Walczak J, Garrett-Mayer E, Moore-Cooper S, Eisenberger MA. A phase II evaluation of imatinib mesylate (G) in stage M0 prostate cancer (PC) patients (pts) on hormonal therapy (HT) with evidence of biochemical relapse Journal of Clinical Oncology. 24: 14612-14612. DOI: 10.1200/Jco.2006.24.18_Suppl.14612 |
0.34 |
|
| 2006 |
Li J, Jameson MB, Baguley BC, Pili R, Baker SD. Population pharmacokinetics (PK) of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in cancer patients Journal of Clinical Oncology. 24: 13076-13076. DOI: 10.1200/Jco.2006.24.18_Suppl.13076 |
0.324 |
|
| 2005 |
Heath EI, Gaskins M, Pitot HC, Pili R, Tan W, Marschke R, Liu G, Hillman D, Sarkar F, Sheng S, Erlichman C, Ivy P. A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clinical Prostate Cancer. 4: 138-41. PMID 16197617 DOI: 10.3816/Cgc.2005.N.024 |
0.371 |
|
| 2005 |
Link RE, Allaf ME, Pili R, Kavoussi LR. Modeling the cost of management options for stage I nonseminomatous germ cell tumors: a decision tree analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5762-73. PMID 16110033 DOI: 10.1200/Jco.2005.09.308 |
0.319 |
|
| 2005 |
Rosenbaum E, Zahurak M, Sinibaldi V, Carducci MA, Pili R, Laufer M, DeWeese TL, Eisenberger MA. Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 4437-43. PMID 15958628 DOI: 10.1158/1078-0432.Ccr-04-2252 |
0.39 |
|
| 2005 |
Wang XF, Qian DZ, Ren M, Kato Y, Wei Y, Zhang L, Fansler Z, Clark D, Nakanishi O, Pili R. Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 3535-42. PMID 15867257 DOI: 10.1158/1078-0432.Ccr-04-1092 |
0.337 |
|
| 2005 |
Lin KS, Luu A, Baidoo KE, Hashemzadeh-Gargari H, Chen MK, Brenneman K, Pili R, Pomper M, Carducci MA, Wagner HN. A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation. Bioconjugate Chemistry. 16: 43-50. PMID 15656574 DOI: 10.1021/Bc049820H |
0.322 |
|
| 2005 |
Qian DZ, Ren M, Wei Y, Wang X, Van De Geijn F, Rasmussen C, Nakanishi O, Sacchi N, Pili R. In vivo imaging of retinoic acid receptor β2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells Prostate. 64: 20-28. PMID 15651062 DOI: 10.1002/Pros.20209 |
0.45 |
|
| 2005 |
Sinibaldi VJ, Elza-Brown K, Stewart J, Rosenbaum E, Denmeade S, Pili R, Walczak J, Baker SD, Zahurak M, Carducci MA. Phase II evaluation of docetaxel (D) plus exisulind (E) in patients (pts) with androgen independent prostate carcinoma (AIPC) Journal of Clinical Oncology. 23: 4758-4758. DOI: 10.1200/Jco.2005.23.16_Suppl.4758 |
0.329 |
|
| 2005 |
Slovin SF, Carducci MA, Beekman KW, Pili R, Eicher C, Kelly WK, Morris MJ, Shaffer D, Eisenberger M, Scher HI. The men’s cycle plus docetaxel (Doc) in prostate cancer patients with rising PSAs in the non-castrate state Journal of Clinical Oncology. 23: 4564-4564. DOI: 10.1200/Jco.2005.23.16_Suppl.4564 |
0.368 |
|
| 2005 |
Bajaj G, Garret-Mayer E, Zhang Z, Drew R, Sinibaldi V, Gaver M, Pili R, Denmeade S, Carducci M, Nelson W, Eisenberger M, DeWeese T. A Phase II Study of Imatinib Mesylate in Prostate Cancer Patients With Evidence of Biochemical Relapse Following Definitive Radical Retropubic Prostatectomy or Radiation Therapy International Journal of Radiation Oncology*Biology*Physics. 63: S312. DOI: 10.1016/J.Ijrobp.2005.07.535 |
0.349 |
|
| 2004 |
Lin KS, Luu A, Baidoo KE, Hashemzadeh-Gargari H, Chen MK, Pili R, Pomper M, Carducci M, Wagner HN. A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic modifier. Bioconjugate Chemistry. 15: 1416-23. PMID 15546210 DOI: 10.1021/Bc0498267 |
0.314 |
|
| 2004 |
Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, Atadja P, Pili R. The histone deacetylase inhibitor NVP-LAQ824 Inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 Cancer Research. 64: 6626-6634. PMID 15374977 DOI: 10.1158/0008-5472.Can-04-0540 |
0.417 |
|
| 2004 |
Karp JE, Gojo I, Pili R, Gocke CD, Greer J, Guo C, Qian D, Morris L, Tidwell M, Chen H, Zwiebel J. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3577-85. PMID 15173063 DOI: 10.1158/1078-0432.Ccr-03-0627 |
0.324 |
|
| 2004 |
Sunkara U, Walczak JR, Summerson L, Rogers T, Eisenberger M, Denmeade S, Pili R, Huff CA, Sinibaldi V, Carducci MA. A Phase II Trial of Temozolomide and IFN-α in Patients with Advanced Renal Cell Carcinoma Journal of Interferon and Cytokine Research. 24: 37-41. PMID 14980083 DOI: 10.1089/107999004772719891 |
0.345 |
|
| 2004 |
Chen C, Cohen M, Chowdhury WH, Pili R, Schoenberg MP, Rodriguez R. 319: Effect of Valproic Acid as a Potential Chemopreventive Agent in Animal Models of Bladder Cancer Journal of Urology. 171: 84-84. DOI: 10.1016/S0022-5347(18)37581-5 |
0.307 |
|
| 2003 |
Pili R, Donehower RC. Is HIF-1α a valid therapeutic target? Journal of the National Cancer Institute. 95: 498-499. PMID 12671009 DOI: 10.1093/Jnci/95.7.498 |
0.365 |
|
| 2002 |
Volpert OV, Pili R, Sikder HA, Nelius T, Zaichuk T, Morris C, Shiflett CB, Devlin MK, Conant K, Alani RM. Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer Cell. 2: 473-83. PMID 12498716 DOI: 10.1016/S1535-6108(02)00209-X |
0.335 |
|
| 2001 |
Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis Cancer Research. 61: 1477-1485. PMID 11245454 |
0.342 |
|
| 1997 |
Pili R, Chang J, Muhlhauser J, Crystal RG, Capogrossi MC, Passaniti A. Adenovirus-mediated gene transfer of fibroblast growth factor-1: Angiogenesis and tumorigenicity in nude mice International Journal of Cancer. 73: 258-263. PMID 9335452 DOI: 10.1002/(Sici)1097-0215(19971009)73:2<258::Aid-Ijc16>3.0.Co;2-B |
0.309 |
|
| 1995 |
Cirielli C, Riccioni T, Yang C, Pili R, Gloe T, Chang J, Inyaku K, Passaniti A, Capogrossi MC. Adenovirus-mediated gene transfer of wild-type p53 results in melanoma cell apoptosis in intro and in vivo International Journal of Cancer. 63: 673-679. PMID 7591284 DOI: 10.1002/Ijc.2910630512 |
0.346 |
|
| 1994 |
Pili R, Guo Y, Chang J, Nakanishi H, Martin GR, Passaniti A. Altered angiogenesis underlying age-dependent changes in tumor growth. Journal of the National Cancer Institute. 86: 1303-14. PMID 7520508 DOI: 10.1093/Jnci/86.17.1303 |
0.334 |
|
| 1994 |
Guo Y, Pili R, Passaniti A. Regulation of prostate-specific antigen gene expression in LNCaP human prostatic carcinoma cells by growth, dihydrotestosterone, and extracellular matrix Prostate. 24: 1-10. PMID 7507237 DOI: 10.1002/Pros.2990240104 |
0.344 |
|
| 1993 |
Pili R, Corda S, Passaniti A, Ziegelstein RC, Heldman AW, Capogrossi MC. Endothelial cell Ca2+ increases upon tumor cell contact and modulates cell-cell adhesion Journal of Clinical Investigation. 92: 3017-3022. PMID 8254056 DOI: 10.1172/Jci116925 |
0.317 |
|
| 1992 |
Bartoloni C, Guidi L, Tricerri A, Patriarca F, Pili R, Cursi F, Canetta M, Cappelli A, Vangeli M, Salvati F, Gambassi G. Latent coagulation disorders evaluated by the assay of plasma thrombin-antithrombin III complexes in a large series of 'solid tumours' Oncology (Switzerland). 49: 426-430. PMID 1465280 DOI: 10.1159/000227086 |
0.33 |
|
| 1987 |
Bartoloni C, Guidi L, Pili R, Lewis ZA, Tricerri A, Cursi F, Gentiioni N, Cortesi E, Gambassi G. Assay, isolation and characterization of circulating immune complexes from serum of gastrointestinal cancer, stage iii and iv melanoma and chronic inflammatory bowel disease patients Oncology (Switzerland). 50: 27-34. DOI: 10.1159/000227143 |
0.321 |
|
| Show low-probability matches. |